WAYNE, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today presented final results from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) of its lead gene therapy candidate XC001 (encoberminogene rezmadenovec) for refractory angina at the Society for Cardiovascular Angiography…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
